Quick Comparison
| Retatrutide | Tirzepatide | |
|---|---|---|
| Class | Triple GIP/GLP-1/glucagon receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Receptors activated | GIP, GLP-1, and glucagon receptors | GIP receptor and GLP-1 receptor |
| Developer | Eli Lilly (LY3437943) | Eli Lilly |
| FDA status | Investigational, Phase 3 (TRIUMPH-1) | FDA-approved (Mounjaro, Zepbound) |
| Weight loss in own pivotal trial | 28.3% at 80 weeks, 12mg (TRIUMPH-1) | Up to 22.5% at 72 weeks, 15mg (SURMOUNT-1) |
| Head-to-head trial vs the other | None published. Any comparison is indirect, across separate trials. | |
Important framing before the numbers below: no clinical trial has ever put retatrutide and tirzepatide head-to-head in the same study. The figures in this article come from each drug's own separate trial program. That's a real limitation worth keeping in mind throughout, not a footnote.
What Each Compound Is
Tirzepatide is a synthetic peptide that activates two incretin hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It's FDA-approved under the brand name Mounjaro for type 2 diabetes and under the brand name Zepbound for chronic weight management, making it one of the most established medications in this drug class.
Retatrutide (Eli Lilly's development code LY3437943) builds on that same dual mechanism and adds a third target, the glucagon receptor, making it a triple agonist. It's being developed by Eli Lilly for obesity, type 2 diabetes, and several related conditions, but it remains an investigational drug candidate still moving through Phase 3 trials and FDA review, not a finished, approved medicine.
That regulatory gap is the single most important difference between the two compounds covered on this page, and it shapes almost everything else: how each one can legally be obtained, what evidence actually exists, and what "research-grade" material sold outside either drug's trial framework actually means.
Mechanism: Two Receptors vs Three
Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide activates those same two receptors and adds glucagon-receptor activity on top. All three pathways sit within the broader incretin and metabolic hormone system that responds to food intake and helps regulate blood sugar, appetite, and energy expenditure.
The added glucagon-receptor activity is the proposed mechanistic reason retatrutide has shown larger weight-loss effects in its own trials than tirzepatide showed in its own trials: glucagon-receptor activation is understood to increase energy expenditure in addition to the appetite-suppressing and insulin-related effects that both drugs share through GIP and GLP-1.
Why "more receptors" isn't automatically "better": each additional receptor pathway is also an additional source of side effects, and a drug that affects energy expenditure through glucagon receptor activity is mechanistically different enough from GIP/GLP-1-only drugs that its safety profile in earlier, smaller trials doesn't automatically predict what wider, longer-term use will show. More targets means more to monitor, not just more effect.
Human Evidence: Two Trial Programs, No Head-to-Head
Tirzepatide's pivotal obesity trial, SURMOUNT-1, found weight loss of up to 22.5% at 72 weeks on the 15mg dose. That result, published in 2022, supported tirzepatide's FDA approval as Zepbound and is one of the most robust human evidence bases of any compound in this category.
Retatrutide's pivotal obesity trial, TRIUMPH-1 (NCT05929066), is a Phase 3, 80-week, randomized, placebo-controlled trial of 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. Participants were randomized to retatrutide 4mg, 9mg, 12mg, or placebo, with doses titrated up from a 2mg starting dose roughly every four weeks.
| TRIUMPH-1, 80 weeks | 4mg | 9mg | 12mg | Placebo |
|---|---|---|---|---|
| Mean weight change | -19.0% (47.2 lb) | -25.9% (64.4 lb) | -28.3% (70.3 lb) | -2.2% (5.5 lb) |
| Reached ≥30% loss | 15.3% | 37.9% | 45.3% | 0.5% |
| Reached BMI <30 | 65.3% of the 12mg group (not multiplicity-controlled) | — | ||
A pre-specified extension followed 532 participants with a baseline BMI of 35 or higher for an additional 24 weeks (104 weeks total), dosed up to their maximum tolerated dose. Participants who stayed on the 12mg dose through the full extension reached 30.3% average weight loss (about 85 lb) from that subgroup's baseline. Lilly announced TRIUMPH-1's topline results on May 21, 2026, with results from the related TRIUMPH-2 and TRIUMPH-3 trials expected later in 2026.
So which one "wins"? Comparing 28.3% (retatrutide, 12mg, 80 weeks) against 22.5% (tirzepatide, 15mg, 72 weeks) is tempting, but these numbers come from two different trials, with different populations, different durations, and years apart. That's evidence that each drug is highly effective in its own right, not evidence that retatrutide would outperform tirzepatide if the two were ever tested in the same trial.
The one cross-trial estimate that exists
A 2025 systematic review published in Annals of Internal Medicine looked at 26 randomized trials across more than 15,000 patients covering semaglutide, tirzepatide, retatrutide, and several other investigational incretin-based drugs. Its authors stated explicitly that they did not find any head-to-head studies between these therapies. Working indirectly across separate trials, the review estimated roughly 22% weight loss for retatrutide (12mg, 48 weeks) versus roughly 18% for tirzepatide (15mg, 72 weeks) versus roughly 14% for semaglutide (2.4mg, 68 weeks).
Two things matter about that estimate. First, it's an indirect comparison across trials, exactly the kind of comparison its own authors warned against treating as a reliable ranking, since differing populations and control groups limit comparability. Second, it was published in January 2025, before TRIUMPH-1's Phase 3 results existed, so even this indirect estimate is based on retatrutide's earlier, smaller Phase 2 data, not the larger, more recent trial data summarized above.
Regulatory Status and Safety
This is where the two compounds diverge most sharply. Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), manufactured by Eli Lilly under full pharmaceutical quality control and available by prescription through a licensed pharmacy. Retatrutide is not approved by the FDA or any other regulator anywhere in the world. It remains in Phase 3 trials, with Lilly targeting a regulatory filing in early 2027 and approval, if granted, unlikely before late 2027.
Despite that unapproved status, material labeled "retatrutide" is already sold by some suppliers as a research chemical, not for human consumption, while the real drug remains inside Lilly's own controlled trial program. As covered in more depth on BioStackIQ's Retatrutide reference page, this is a bigger red flag than most unapproved research peptides: it means a known, actively studied drug candidate is being diverted or replicated outside the manufacturing, purity, and dosing controls of its own trial, and the FDA has issued warning letters over exactly this. Tirzepatide sold as a research chemical, separate from the approved Mounjaro/Zepbound product, carries a related but distinct problem: it's not an active trial drug being diverted, but it still has not been evaluated by the FDA for human use.
Both drugs produce primarily gastrointestinal side effects. In TRIUMPH-1, nausea occurred in 28.6% (4mg), 38.4% (9mg), and 42.4% (12mg) of participants versus 14.8% on placebo; diarrhea in 25.2%, 34.1%, and 32.0% versus 13.5%; vomiting in 10.6%, 22.8%, and 25.3% versus 4.8%. Discontinuation due to adverse events rose with dose, from 4.1% (4mg) to 11.3% (12mg), versus 4.9% on placebo. This dose-dependent GI pattern is consistent with what's reported for tirzepatide and other incretin-based drugs, and it's most pronounced during dose escalation for both compounds.
What They Have in Common, and What's Different
In common: both are incretin-based peptides developed by Eli Lilly that activate the GIP and GLP-1 receptors, both are titrated up gradually from a low starting dose, and both share a similar gastrointestinal side effect profile that's most noticeable during dose escalation.
Different: tirzepatide activates two receptors and is FDA-approved; retatrutide activates three (adding glucagon) and remains investigational. Tirzepatide can be legally obtained by prescription today; retatrutide cannot be legally used outside a clinical trial. And while retatrutide's own trial has shown a larger weight-loss effect than tirzepatide's own trial, that comparison is between two separate studies, not one trial that tested both drugs on the same patients.
Bloodwork to Track
Fasting glucose and HbA1c both reflect blood sugar control and are useful for tracking either compound's effect over time; see how the two markers relate in the fasting glucose vs HbA1c comparison. Fasting insulin reflects insulin sensitivity, which often improves alongside weight loss on either drug. A lipid panel is also worth tracking, since metabolic improvements frequently show up in cholesterol and triglyceride markers too. See the full peptide bloodwork guide for the rest of the core panel.
Choosing Between Them
For most people today, this isn't really a choice between two available options. Tirzepatide is an FDA-approved prescription medication a healthcare provider can prescribe now. Retatrutide is not available outside a clinical trial, and material sold as retatrutide outside that framework carries the regulatory and quality concerns described above. What this comparison can offer is context: the mechanistic difference between a dual-receptor and triple-receptor approach, what each drug's own trial has actually shown, and a clear-eyed read on why no study has directly pitted the two against each other. BioStackIQ's Fat Loss Calculator can help frame realistic expectations around a weight management goal, and Rate My Stack can help evaluate how a broader protocol fits together once a direction is set with a provider.